Application of a self-controlled case series study to a database study in children

Hanae Ueyama, Shiro Hinotsu, Shiro Tanaka, Hisashi Urushihara, Masaki Nakamura, Yuji Nakamura, Koji Kawakami

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Introduction: Post-marketing surveillance activities are particularly important for safety issues in children, the elderly, and patients with severe comorbidities since these populations are usually excluded from clinical trials. In addition, using electronic databases for monitoring of safety of marketed products has been of considerable interest. Objectives: This study aimed to clarify the advantages and difficulties of the self-controlled case series method relative to cohort studies in pharmacoepidemiological studies in children, using an administrative database, and to explore the impact on results of handling the period eligible for analysis and recurrent events in different ways. Methods: Datasets of only individuals who had the outcome of interest were derived from an anonymized hospital administrative database in Japan from April 2003 through August 2011. We calculated incidence rate ratios (IRRs) and their 95 % confidence intervals (CIs) for the risks of diarrhea, bronchitis, and eczema related to palivizumab treatment in young children. The analysis included 'first diagnosed' events or 'multiple' events during an eligible period. An eligible period was defined in two ways: first-time inpatient periods of more than 3 continuous days (EPA); and a continuous period in cases where the interval between visits was below the 75th percentile of the interval between visits for patients with the same diagnosis (EPB). Results: We extracted data for 70,771 patients and identified 641 who were exposed to palivizumab. The age-adjusted IRRs for diarrhea, bronchitis, and eczema were 3.0 (95 % CI 1.7-5.4), 10.3 (95 % CI 8.0-13.2), and 16.9 (95 % CI 12-23), respectively, in multiple events and the EPB eligible period. The IRRs varied greatly between the two eligible periods. Conclusions: This method could be a useful tool in pharmacoepidemiological studies in children. Careful consideration in the handling of inpatient and outpatient periods, including sensitivity analyses, is necessary because this method is a within-individual comparison.

Original languageEnglish
Pages (from-to)259-268
Number of pages10
JournalDrug Safety
Volume37
Issue number4
DOIs
Publication statusPublished - 2014
Externally publishedYes

Fingerprint

Databases
Confidence Intervals
Bronchitis
Eczema
Inpatients
Diarrhea
Incidence
Safety
Marketing
Comorbidity
Japan
Cohort Studies
Outpatients
Monitoring
Demography
Clinical Trials
Population
Palivizumab
Therapeutics
Datasets

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology
  • Toxicology
  • Medicine(all)

Cite this

Ueyama, H., Hinotsu, S., Tanaka, S., Urushihara, H., Nakamura, M., Nakamura, Y., & Kawakami, K. (2014). Application of a self-controlled case series study to a database study in children. Drug Safety, 37(4), 259-268. https://doi.org/10.1007/s40264-014-0148-9

Application of a self-controlled case series study to a database study in children. / Ueyama, Hanae; Hinotsu, Shiro; Tanaka, Shiro; Urushihara, Hisashi; Nakamura, Masaki; Nakamura, Yuji; Kawakami, Koji.

In: Drug Safety, Vol. 37, No. 4, 2014, p. 259-268.

Research output: Contribution to journalArticle

Ueyama, H, Hinotsu, S, Tanaka, S, Urushihara, H, Nakamura, M, Nakamura, Y & Kawakami, K 2014, 'Application of a self-controlled case series study to a database study in children', Drug Safety, vol. 37, no. 4, pp. 259-268. https://doi.org/10.1007/s40264-014-0148-9
Ueyama, Hanae ; Hinotsu, Shiro ; Tanaka, Shiro ; Urushihara, Hisashi ; Nakamura, Masaki ; Nakamura, Yuji ; Kawakami, Koji. / Application of a self-controlled case series study to a database study in children. In: Drug Safety. 2014 ; Vol. 37, No. 4. pp. 259-268.
@article{9f2fa3e171984ae6ace030559331be85,
title = "Application of a self-controlled case series study to a database study in children",
abstract = "Introduction: Post-marketing surveillance activities are particularly important for safety issues in children, the elderly, and patients with severe comorbidities since these populations are usually excluded from clinical trials. In addition, using electronic databases for monitoring of safety of marketed products has been of considerable interest. Objectives: This study aimed to clarify the advantages and difficulties of the self-controlled case series method relative to cohort studies in pharmacoepidemiological studies in children, using an administrative database, and to explore the impact on results of handling the period eligible for analysis and recurrent events in different ways. Methods: Datasets of only individuals who had the outcome of interest were derived from an anonymized hospital administrative database in Japan from April 2003 through August 2011. We calculated incidence rate ratios (IRRs) and their 95 {\%} confidence intervals (CIs) for the risks of diarrhea, bronchitis, and eczema related to palivizumab treatment in young children. The analysis included 'first diagnosed' events or 'multiple' events during an eligible period. An eligible period was defined in two ways: first-time inpatient periods of more than 3 continuous days (EPA); and a continuous period in cases where the interval between visits was below the 75th percentile of the interval between visits for patients with the same diagnosis (EPB). Results: We extracted data for 70,771 patients and identified 641 who were exposed to palivizumab. The age-adjusted IRRs for diarrhea, bronchitis, and eczema were 3.0 (95 {\%} CI 1.7-5.4), 10.3 (95 {\%} CI 8.0-13.2), and 16.9 (95 {\%} CI 12-23), respectively, in multiple events and the EPB eligible period. The IRRs varied greatly between the two eligible periods. Conclusions: This method could be a useful tool in pharmacoepidemiological studies in children. Careful consideration in the handling of inpatient and outpatient periods, including sensitivity analyses, is necessary because this method is a within-individual comparison.",
author = "Hanae Ueyama and Shiro Hinotsu and Shiro Tanaka and Hisashi Urushihara and Masaki Nakamura and Yuji Nakamura and Koji Kawakami",
year = "2014",
doi = "10.1007/s40264-014-0148-9",
language = "English",
volume = "37",
pages = "259--268",
journal = "Drug Safety",
issn = "0114-5916",
publisher = "Adis International Ltd",
number = "4",

}

TY - JOUR

T1 - Application of a self-controlled case series study to a database study in children

AU - Ueyama, Hanae

AU - Hinotsu, Shiro

AU - Tanaka, Shiro

AU - Urushihara, Hisashi

AU - Nakamura, Masaki

AU - Nakamura, Yuji

AU - Kawakami, Koji

PY - 2014

Y1 - 2014

N2 - Introduction: Post-marketing surveillance activities are particularly important for safety issues in children, the elderly, and patients with severe comorbidities since these populations are usually excluded from clinical trials. In addition, using electronic databases for monitoring of safety of marketed products has been of considerable interest. Objectives: This study aimed to clarify the advantages and difficulties of the self-controlled case series method relative to cohort studies in pharmacoepidemiological studies in children, using an administrative database, and to explore the impact on results of handling the period eligible for analysis and recurrent events in different ways. Methods: Datasets of only individuals who had the outcome of interest were derived from an anonymized hospital administrative database in Japan from April 2003 through August 2011. We calculated incidence rate ratios (IRRs) and their 95 % confidence intervals (CIs) for the risks of diarrhea, bronchitis, and eczema related to palivizumab treatment in young children. The analysis included 'first diagnosed' events or 'multiple' events during an eligible period. An eligible period was defined in two ways: first-time inpatient periods of more than 3 continuous days (EPA); and a continuous period in cases where the interval between visits was below the 75th percentile of the interval between visits for patients with the same diagnosis (EPB). Results: We extracted data for 70,771 patients and identified 641 who were exposed to palivizumab. The age-adjusted IRRs for diarrhea, bronchitis, and eczema were 3.0 (95 % CI 1.7-5.4), 10.3 (95 % CI 8.0-13.2), and 16.9 (95 % CI 12-23), respectively, in multiple events and the EPB eligible period. The IRRs varied greatly between the two eligible periods. Conclusions: This method could be a useful tool in pharmacoepidemiological studies in children. Careful consideration in the handling of inpatient and outpatient periods, including sensitivity analyses, is necessary because this method is a within-individual comparison.

AB - Introduction: Post-marketing surveillance activities are particularly important for safety issues in children, the elderly, and patients with severe comorbidities since these populations are usually excluded from clinical trials. In addition, using electronic databases for monitoring of safety of marketed products has been of considerable interest. Objectives: This study aimed to clarify the advantages and difficulties of the self-controlled case series method relative to cohort studies in pharmacoepidemiological studies in children, using an administrative database, and to explore the impact on results of handling the period eligible for analysis and recurrent events in different ways. Methods: Datasets of only individuals who had the outcome of interest were derived from an anonymized hospital administrative database in Japan from April 2003 through August 2011. We calculated incidence rate ratios (IRRs) and their 95 % confidence intervals (CIs) for the risks of diarrhea, bronchitis, and eczema related to palivizumab treatment in young children. The analysis included 'first diagnosed' events or 'multiple' events during an eligible period. An eligible period was defined in two ways: first-time inpatient periods of more than 3 continuous days (EPA); and a continuous period in cases where the interval between visits was below the 75th percentile of the interval between visits for patients with the same diagnosis (EPB). Results: We extracted data for 70,771 patients and identified 641 who were exposed to palivizumab. The age-adjusted IRRs for diarrhea, bronchitis, and eczema were 3.0 (95 % CI 1.7-5.4), 10.3 (95 % CI 8.0-13.2), and 16.9 (95 % CI 12-23), respectively, in multiple events and the EPB eligible period. The IRRs varied greatly between the two eligible periods. Conclusions: This method could be a useful tool in pharmacoepidemiological studies in children. Careful consideration in the handling of inpatient and outpatient periods, including sensitivity analyses, is necessary because this method is a within-individual comparison.

UR - http://www.scopus.com/inward/record.url?scp=84898796751&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84898796751&partnerID=8YFLogxK

U2 - 10.1007/s40264-014-0148-9

DO - 10.1007/s40264-014-0148-9

M3 - Article

VL - 37

SP - 259

EP - 268

JO - Drug Safety

JF - Drug Safety

SN - 0114-5916

IS - 4

ER -